AstraZeneca PLC Takes On Merck & Co., Inc. In Alzheimer's Drug Race

Published: Feb 07, 2014

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

AstraZeneca is moving an experimental Alzheimer's drug into late-stage development, taking on U.S. rival Merck & Co which announced plans to start similar final-stage research in December. Britain's second-biggest drugmaker revealed its plan to move AZD3293 into the last phase of testing needed for registration as it announced full-year results on Thursday. Both the AstraZeneca and Merck medicines work by blocking an enzyme called beta secretase that is involved in production of beta-amyloid, a protein that creates brain plaques considered a major cause of Alzheimer's disease.

Help employers find you! Check out all the jobs and post your resume.

Back to news